AI GxP validation for regulated life sciences
Med Device

21 CFR Part 820 and the QMSR: what FDA requires of device makers since February 2026

21 CFR Part 820 is FDA's quality system rule for medical devices. Since 2 February 2026 it is the Quality Management System Regulation (QMSR), built on ISO 13485:2016. What the rule now contains, what replaced the old QSR sections such as 820.30 design controls, and what FDA can now inspect.

Cybroscape Technologies8 min read

Key takeaway

21 CFR Part 820 is FDA's quality system rule for medical devices. Since 2 February 2026 it is the Quality Management System Regulation (QMSR), built on ISO 13485:2016. What the rule now contains, what replaced the old QSR sections such as 820.30 design controls, and what FDA can now inspect.

21 CFR Part 820 is the US rule that sets the quality system requirements for medical device manufacturers. Since 2 February 2026 it is called the Quality Management System Regulation (QMSR). The old Quality System Regulation (QSR) wrote its own requirements section by section. Part 820 now incorporates ISO 13485:2016 by reference and adds a short list of FDA-specific requirements on top.

FDA published the final rule on 2 February 2024 and gave manufacturers two years to move over. If you already run an ISO 13485 quality system, most of the work is done. The parts that catch teams out are the ones FDA kept for itself, and the records FDA can now ask to see.

QSR vs QMSR: what changed

  • The source of the requirements. The QSR had its own sections (820.20 management responsibility, 820.30 design controls, 820.50 purchasing controls and so on). The QMSR withdraws most of them and points to the clauses of ISO 13485:2016 instead.
  • The name. Quality System Regulation became Quality Management System Regulation, matching ISO language.
  • The records FDA can review. Under the QSR, internal audit reports, supplier audit reports and management review were exempt from FDA inspection. That exemption is gone. FDA has said it intends to review these records from 2 February 2026, and may look at ones created before that date.
  • Terms. The QSR's device master record, device history record and design history file are no longer defined terms. The equivalent content lives in ISO 13485 records such as the medical device file and the design and development file.
  • What stayed. The scope, some definitions, and a few FDA-specific requirements where FDA judged ISO 13485 not specific enough.

What Part 820 contains now

The rule is short. Subpart A holds the general provisions: scope (820.1), definitions (820.3), the incorporation of ISO 13485 by reference (820.7) and the core requirement to establish and maintain a quality management system (820.10). Subpart B holds two supplemental provisions:

  • 820.35, control of records. Builds on ISO 13485 clause 4.2.5 and spells out content FDA wants in specific records, such as complaint and servicing records.
  • 820.45, device labeling and packaging controls. Keeps the old QSR labeling controls because ISO 13485 has no equally specific clause: labeling is checked for accuracy before release, and controls must prevent mix-ups.

Read the current text on the eCFR rather than a summary, including ours. The wording of 820.10 matters, because it is where FDA ties the ISO clauses to its other device rules.

Old QSR sections and where they went in ISO 13485

Many procedures and searches still use the old section numbers. This is where each main QSR section now lives. Check the clause text itself before you rewrite a procedure, because the ISO wording is not identical.

  • 820.20 management responsibility (quality policy, quality objectives, management review): ISO 13485 clause 5, including 5.3 quality policy, 5.4.1 quality objectives and 5.6 management review.
  • 820.22 quality audit: clause 8.2.4, internal audit.
  • 820.25 personnel and training: clause 6.2, human resources.
  • 820.30 design controls: clause 7.3, design and development.
  • 820.40 document controls: clause 4.2.4, control of documents.
  • 820.50 purchasing controls: clause 7.4, purchasing.
  • 820.70 production and process controls: clause 7.5.1, with 6.3 infrastructure and 6.4 work environment.
  • 820.72 inspection, measuring and test equipment: clause 7.6, control of monitoring and measuring equipment.
  • 820.75 process validation: clause 7.5.6, validation of processes for production and service provision.
  • 820.90 nonconforming product: clause 8.3.
  • 820.100 corrective and preventive action (CAPA): clauses 8.5.2 corrective action and 8.5.3 preventive action.
  • 820.120 and 820.130 labeling and packaging: kept by FDA in 820.45.
  • 820.180 records: clause 4.2.5, plus FDA's own 820.35.
  • 820.198 complaint files: clause 8.2.2, complaint handling, plus the record content in 820.35.
  • 820.200 servicing: clause 7.5.4, servicing activities, plus 820.35.

QMSR vs ISO 13485: what is different

The QMSR harmonizes FDA's rule with ISO 13485:2016, but the two are not the same document. The QMSR adds FDA's own definitions, the record content in 820.35, the labeling and packaging controls in 820.45, and the link to other FDA rules. Where an FDA definition differs from an ISO term, FDA's definition applies. ISO 13485 on its own does none of that, and a certification body audit is not an FDA inspection.

What happened to 21 CFR 820.30 design controls

Section 820.30 no longer exists in its old form. Design controls now come from ISO 13485 clause 7.3, design and development, which covers the same ground: planning, inputs, outputs, review, verification, validation, transfer, changes and the design and development file. As before, design controls apply to Class II and Class III devices and to the Class I devices FDA lists.

In practice, a design control procedure written for 820.30 usually maps cleanly to clause 7.3. The gaps tend to be in terms, such as design history file versus design and development file. They also show up in clause 7.3.9, control of design and development changes. That clause asks you to assess the effect of a change on product already delivered.

The FDA rules that sit alongside ISO 13485

An ISO 13485 certificate does not make a company QMSR compliant, and it does not replace an FDA inspection. FDA does not issue or accept certificates in place of its own review.

Other device rules still apply next to the QMSR. They include labeling (21 CFR Part 801), unique device identification (21 CFR Part 830), device tracking (21 CFR Part 821) and medical device reporting (21 CFR Part 803). Electronic records and signatures in the quality system are still subject to 21 CFR Part 11; the QMSR did not change that. Check that your procedures cite them where ISO 13485 is silent.

QMSR gap assessment: a practical check

  • Procedures. Replace references to QSR sections with ISO 13485 clauses, and keep the FDA-specific ones (820.35, 820.45, Parts 803, 821, 830) where they apply.
  • Audit and management review records. Write them on the assumption that an investigator will read them. Findings with no follow-up, or a management review with no decisions, now show up.
  • Risk. ISO 13485 asks for a risk-based approach across the quality system, not only in design. Expect questions about how risk shaped supplier controls, software validation and sampling.
  • Software used in the quality system. ISO 13485 clause 4.1.6 requires validation of software used in the quality management system, proportionate to risk. FDA's Computer Software Assurance guidance was reissued in February 2026 to align with the QMSR; see CSA and QMSR for medical device software for how the two fit.
  • Training. People who learned the QSR section numbers need the new map, or the old numbers will keep appearing in new documents.

Where software can help

Most of the QMSR work is document and process work: procedures, CAPA, complaints, supplier controls and the records FDA can now review. An eQMS implementation project or our own Cybroscape eQMS handles that side. Cybroscape GxP Copilot covers validation of the software and equipment the quality system depends on. Neither replaces the judgement of the people who own the quality system; they shorten the paperwork around it.

Where to go next

Explore Cybroscape GxP Copilot for AI-native validation, Cybroscape TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.

Part of our guide to GxP software — categories, evaluation criteria and how the platforms compare.

Validation planReported inValidation summary report
User requirements (URS)verified byPerformance qualification (PQ)
Functional specification (FS)verified byOperational qualification (OQ)
Design specification (DS)verified byInstallation qualification (IQ)
Build and configure the system
Risk assessment at every stageTraceability matrix links each row
The V-model under GAMP 5: each specification on the left is verified by the qualification on the right, and the traceability matrix links every row. Risk assessment runs through all of it.
See it on your own systemBring a URS or a system. We run GxP Copilot against it live on the call.
21 cfr part 82021 cfr 820fda 21 cfr part 820qmsrfda qsrquality system regulation21 cfr 820.30qmsr iso 13485
FAQ

Frequently Asked Questions

Prefer to talk first? Chat with us on WhatsApp or book a call with an expert.

What is 21 CFR Part 820?

21 CFR Part 820 is the FDA regulation that sets quality system requirements for medical device manufacturers. Since 2 February 2026 it is the Quality Management System Regulation (QMSR), which incorporates ISO 13485:2016 by reference and adds a small number of FDA-specific requirements.

Is the FDA QSR still in effect?

No. The Quality System Regulation was replaced by the QMSR on 2 February 2026. The regulation is still 21 CFR Part 820, but most of its old sections were withdrawn in favour of ISO 13485:2016.

What replaced 21 CFR 820.30 design controls?

ISO 13485:2016 clause 7.3, design and development, incorporated into Part 820 by reference. It covers the same activities as 820.30. Design controls still apply to Class II and Class III devices and to the Class I devices FDA lists.

Does an ISO 13485 certificate mean you comply with the QMSR?

No. FDA does not accept certificates in place of its own inspection. Part 820 also adds requirements ISO 13485 does not have, such as the record content in 820.35 and the labeling and packaging controls in 820.45. Rules such as UDI (Part 830) and device tracking (Part 821) also still apply.

Is 21 CFR 820 still valid?

Yes. 21 CFR Part 820 is still the regulation, but since 2 February 2026 it is the Quality Management System Regulation (QMSR) rather than the Quality System Regulation (QSR). The old section numbers such as 820.30 and 820.100 no longer exist in their previous form.

Where did 21 CFR 820.100 CAPA go?

Corrective and preventive action now comes from ISO 13485:2016 clauses 8.5.2 (corrective action) and 8.5.3 (preventive action), incorporated into Part 820 by reference.

Can FDA now review internal audit and management review records?

Yes. The QSR exempted internal audit reports, supplier audit reports and management review from FDA inspection. That exemption ended with the QMSR, and FDA has said it intends to review these records.

Keep reading

All articles
Med DeviceMDR CERs with AI: traceable clinical claims, hash-chained auditThe MDR clinical evidence burden meets a source-traceable AI writing platform. · 5 min readMed DeviceCSA and QMSR for medical device manufacturers: what changedFDA’s final CSA guidance covers production and quality system software, not device software. It scales testing and records to process risk, and fits with ISO 13485 under QMSR, effective February 2026. · 3 min readIntegrationELN-LIMS Integration for Mid-Sized Pharma: Architecture, Validation, and Common PitfallsHow mid-sized pharma teams architect, validate, and maintain ELN-to-LIMS integrations: the GAMP 5 framework applied, and real failure modes from the field. · 5 min readeQMSValidating an eQMS without re-testing the vendor's softwareValidate an eQMS by relying on the vendor’s evidence for standard functions and testing your own configuration: routing, approvals, signature meanings, migrated records and a routine for cloud releases. · 3 min readThought LeadershipEquipment qualification and computer validation should not be separate worldsModern equipment is software-controlled, so keeping equipment qualification and computer validation separate leaves gaps in data integrity and change control. Use one risk approach, clear ownership of every boundary and one record of each asset's state. · 3 min readThought LeadershipThe EU AI Act won't regulate most pharma AI. GMP will.For most AI in pharmaceutical GxP work, the rules that bite are GMP, GCP, pharmacovigilance and data integrity, not the EU AI Act. The Act matters mainly for device AI, HR tools and the AI literacy duty. · 3 min readTest AutomationWhat an Automated Execution Has to Capture to Count as EvidenceA green tick is not evidence. The specific record an automated run needs to leave behind so that someone reading it in three years can tell what was tested, against what, and by whose authority. · 4 min readGxP AIExplainable AI in GxP Validation: Why Black-Box Models Fail Inspection and What to Use InsteadWhy GxP regulators reject black-box AI, what explainability actually means in a validated environment, and the architectural patterns that make AI decisions auditable and defensible. · 6 min read

Bring a system. We'll show you the package.

Book a demo, or ask a validation lead a quick question on WhatsApp.

  • We reply within one business day
  • We run your URS live on the call
  • You get a clear plan for your system
Chat on WhatsApp

Book a demo

Four fields. The right specialist replies within one business day.

Your details stay private. We never share them.